Vyleesi

Vyleesi: Another Attempt to Profit from Women’s Health 

By NWHN Staff | Dec 23, 2019 | Comments Off on Vyleesi: Another Attempt to Profit from Women’s Health 

In June, the Food and Drug Administration (FDA) approved bremelanotide (brand name Vyleesi) to treat a lack of sexual desire in premenopausal women.1 The NWHN advocated against the drug’s approval, and spoke in opposition when the approval announcement was made. Here’s why.  

Consumer Health Info: Vyleesi

By NWHN Staff | Jul 12, 2019 | Comments Off on Consumer Health Info: Vyleesi

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

The NWHN’s Statement on the FDA’s Approval of Vyleesi

By Cindy Pearson | Jun 21, 2019 | Comments Off on The NWHN’s Statement on the FDA’s Approval of Vyleesi

FOR IMMEDIATE RELEASE Contact: Evita Almassi, [email protected] or 425-749-1886

Top 10 Things to Know About Today’s Sex Drive Drugs

By NWHN Staff | Oct 15, 2015 | Comments Off on Top 10 Things to Know About Today’s Sex Drive Drugs

Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.